Table 1.
Overall study characteristics.
| Characteristics | N (%) |
|---|---|
| Population (n = 97) | |
| Healthcare workers | 41 (42.2) |
| General public | 30 (30.9) |
| Patients/quarantined individuals | 26 (26.6) |
| Outbreaks (n = 95) | |
| SARS | 59 (62.1) |
| Influenza | 14 (14.7) |
| MERS-CoV | 12 (12.6) |
| COVID-19 | 10 (10.5) |
| Mental health outcomes (n = 156) | |
| Post-traumatic stress disorder | 43 (27.6) |
| Anxiety | 42 (26.9) |
| Depression | 34 (21.8) |
| Others | 37 (23.7) |
| Countries/regions (n = 98) | |
| Hong Kong | 31 (31.6) |
| China | 21 (21.4) |
| Taiwan | 10 (10.2) |
| Singapore | 10 (10.2) |
| South Korea | 9 (9.2) |
| Canada | 8 (8.2) |
| Saudi Arabia | 2 (2.0) |
| United States | 2 (2.0) |
| Others (Greece, India, Japan, Mexico, United Kingdom) | 5 (5.1) |
| Study period (n = 97) | |
| During outbreak | 52 (53.6) |
| After outbreak | 40 (41.2) |
| Both during and after outbreak | 5 (5.2) |
| Study design (n = 97) | |
| Cross-sectional | 75 (77.3) |
| Cohort study | 18 (18.6) |
| Case–control | 4 |